The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

Affiliations

• 1 Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.
• 2 Department of Medicine, Harvard Medical School, Boston, MA, USA.
• 3 Department of Pathology, Boston University Medical Center, Boston, MA, USA.
• 4 Theagenio Cancer Hospital, Thessaloniki, Greece.
• 5 Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA. steven_treon@dfci.harvard.edu.
• 6 Department of Medicine, Harvard Medical School, Boston, MA, USA. steven_treon@dfci.harvard.edu.